Already a Bloomberg.com user?
Sign in with the same account.
(Updates with closing share price in second paragraph)
Jan. 24 (Bloomberg) -- BioLineRx Ltd. surged the most on record after the Israeli company that develops therapeutic pharmaceutical drugs signed a deal with France’s Genoscience to develop and commercialize a treatment.
The shares surged 37 percent, the most since February 2007 when Bloomberg started tracking them, to 1.645 shekels at the 4:30 p.m. close in Tel Aviv.
BioLineRx signed an “exclusive license agreement” with Genoscience for its BL-8020 oral treatment for Hepatitis C, it said in a filing with the Tel Aviv Stock Exchange.
--Editors: Daliah Merzaban, Claudia Maedler
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com